GLMD - Galmed Pharmaceuticals Ltd.
| Previous Close | 9.56 |
| Open | 9.54 |
| Bid | 9.67 x 100 |
| Ask | 9.74 x 900 |
| Day's Range | 9.03 - 10.19 |
| 52 Week Range | 3.61 - 27.06 |
| Volume | 157,470 |
| Avg. Volume | 154,812 |
| Market Cap | 201.636M |
| Beta (3Y Monthly) | 3.37 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | May 14, 2018 - May 18, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.14 |
- PR Newswire•2 hours ago
Phase 2 Data for Galmed Pharmaceutical's Aramchol™ in Non-Alcoholic Steatohepatitis (NASH) Presented During Late-Breaking Abstract Oral Session of The Liver Meeting® 2018
TEL AVIV, Israel, Nov. 13, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH") and fibrosis, announced today the oral abstract presentation of one-year results of the Company's global Phase 2b ARREST study of Aramchol in patients with non-alcoholic steatohepatitis (NASH).
- Zacks•9 hours ago
Galmed Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Galmed Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•8 days ago
Galmed Pharmaceuticals (GLMD) Reports Q3 Loss, Tops Revenue Estimates
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of 64.29% and 400.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•8 days ago
Galmed Pharmaceuticals: 3Q Earnings Snapshot
The Tel Aviv, Israel-based company said it had a loss of 5 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
- PR Newswire•8 days ago
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2018 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Nov. 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- Insider Monkey•13 days ago
Nantahala Capital Management’s Returns, AUM, and Holdings
Nantahala Capital Management is a New Haven-based hedge fund founded in 2004 by 26-year-old Wilmot Harkey. He named his firm after the river in the Smoky Mountains which he visited with his family when he was a kid, as he wanted a name that would remind him of his background. Although, Wil Harkey was very young […]
- PR Newswire•15 days ago
Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5
TEL AVIV, Israel , Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- Simply Wall St.•last month
Who Really Owns Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)?
A look at the shareholders of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...
- PR Newswire•last month
Galmed Pharmaceuticals Announces a Late-Breaking Abstract on Aramchol™ to be Presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting®
TEL AVIV, Israel , Oct. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- PR Newswire•2 months ago
Galmed Pharmaceuticals to Present at the Cantor Global Healthcare Conference, ROTH Battle of the NASH Thrones Investor Conference and Stifel Healthcare Conference
TEL AVIV, Israel , Sept. 27, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator ...
- Zacks•3 months ago
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
Medical-Drugs Stock Outlook: No Respite from Near-Term Pain
- Zacks•3 months ago
Galmed Pharmaceuticals (GLMD) Reports Q2 Loss
Galmed Pharmaceuticals (GLMD) delivered earnings and revenue surprises of -6.25% and 0.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Galmed Pharmaceuticals: 2Q Earnings Snapshot
On a per-share basis, the Tel Aviv, Israel-based company said it had a loss of 17 cents. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
- PR Newswire•3 months ago
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2018 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. EST / 5:30 a.m. PST - TEL AVIV, Israel , Aug. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), ...
- PR Newswire•4 months ago
Galmed Pharmaceuticals to Report Second Quarter 2018 Financial Results and Provide Business Update on Thursday, August 2
TEL AVIV, Israel , July 26, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
- Zacks•4 months ago
What's in Store for Universal Health's (UHS) Q2 Earnings?
Universal Health's (UHS) Q2 is likely to benefit from strong performances at its Acute Care and Behavioral Health segments.
- Zacks•4 months ago
What's in the Cards for HCA Healthcare (HCA) in Q2 Earnings?
HCA Healthcare's (HCA) Q2 results are likely to be aided by a strong top line, riding on higher admissions, partially offset by increasing costs.
- Motley Fool•4 months ago
Here's Why Galmed Pharmaceuticals Ltd. Was Up 19% Today and 33% for the Week
Analysts love this biotech, but should you?
- Benzinga•4 months ago
Galmed Notches Second Bullish Rating On Aramchol Opportunity
Two days after Cantor Fitzgerald gave Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) a shot in the arm with an ultrabullish rating , Stifel Nicolaus administered a booster. Galmed spiked 15 percent Friday ...
- ACCESSWIRE•4 months ago
Today's Research Reports on Stocks to Watch: Galmed Pharmaceuticals and Zogenix
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / An analyst at Cantor Fitzgerald thinking that Galmed Pharmaceuticals is undervalued in the NASH space had traders cheering on Thursday, sending shares higher ...
- Market Realist•4 months ago
Galmed Stock Rose Over 26% on ‘Overweight’ Rating
Galmed Stock Rose Over 26% on 'Overweight' RatingGalmed Pharmaceuticals coverage initiated by Cantor Fitzgerald
- Benzinga•4 months ago
Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) earned another bullish analyst this week with a positive rating from Cantor Fitzgerald. The coverage comes with a valuation that implies 459-percent upside. The ...
- ACCESSWIRE•4 months ago
Today's Research Reports on Trending Tickers: Galmed Pharmaceuticals and Akcea Therapeutics
The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors. “If the trade skirmish escalates into a full-blown trade war, that will be a bigger force in the markets than the strong fundamentals,” Carter added.
- Motley Fool•5 months ago
This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It
This NASH drug developer has a decent chance at beating all of its peers to market.
- ACCESSWIRE•5 months ago
Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock
Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.
